Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.4150 -0.0150 (-3.49%)
Official Closing Price Updated: 8:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,949,570
Open 0.4208
Bid (Size) 0.4101 (11)
Ask (Size) 0.4150 (299)
Prev. Close 0.4300
Today's Range 0.4000 - 0.4289
52wk Range 0.2100 - 0.7380
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notification of Additional US Patent for Proprietary Deuterated Psilocybin Analog Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
From Cybin Inc.
Via Business Wire

Performance

YTD
+36.96%
+36.96%
1 Month
-23.99%
-23.99%
3 Month
+30.09%
+30.09%
6 Month
+76.60%
+76.60%
1 Year
+28.72%
+28.72%

More News

Read More
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Four Poster Presentations at the 2023 ACNP Annual Meeting
Via Investor Brand Network
Analyst Expectations for Cybin's Future
Via Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Via Benzinga
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
From Cybin Inc.
Via Business Wire
Cybin's Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What's Next?
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Topline Safety, Efficacy Data for MDD Study
Via Investor Brand Network
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
From Cybin Inc.
Via Business Wire
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host CYB003 Topline Depression Study Review, Briefing
Via Investor Brand Network
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
From Cybin Inc.
Via Business Wire
Expedia To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release, Discuss Topline Safety and Efficacy Data for MDD Study during Upcoming Event
Via Investor Brand Network
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
From Cybin Inc.
Via Business Wire
Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Poster Presentation at Neuroscience 2023, Closing of Underwritten Offering and Q2 Results, Recent Business Highlights
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
From Cybin Inc.
Via Business Wire
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders
From Cybin Inc.
Via Business Wire
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Cybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Deal
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces up to US$64M Offering
Via Investor Brand Network
Cybin Announces up to US$64 Million Offering of Units
From Cybin Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.